Stallergenes Greer
| Stallergenes Greer plc | |
|---|---|
| legal form | Public limited company |
| ISIN | GB00BZ21RF93 |
| founding | 1962 |
| Seat |
London , UK
|
| management | Christian Chavy ( CEO ) |
| Number of employees | 1197 |
| sales | 277 million euros |
| Branch | Pharmaceutical products |
| Website | www.stallergenesgreer.com |
| As of December 31, 2018 | |
Stallergenes Greer is a global pharmaceutical company specializing in the treatment of allergies such as allergic rhinitis (hay fever) and asthma .
Company key figures
In 2018 the annual turnover was 277 million euros internationally. Stallergenes is now the seventh largest pharmaceutical company in France and the second largest company worldwide in the field of allergen immunotherapy. The company employs over 1197 people in 21 countries.
Company history
Stallergenes was founded in 1962 in Lyon at the Institut Mérieux. Until 1974, the company focused on the Benelux countries and North Africa. In the late 1980s, Stallergenes was able to supply some of the world's first orally administered anti-allergy vaccines. In 1989 Stallergenes and the Pasteur Institute merged their manufacturing activities and started a joint research project.
In 1998 the company's shares were listed on the Paris Stock Exchange.
The first sublingual immunotherapy solutions were introduced in various countries in 2002, and in 2004 the only approved tree pollen SLIT Staloral300 . In 2008 the 5-grass tablet Oralair was launched in Germany, which has also been approved in the USA since 2014. In 2011 a new production unit for raw materials was opened.
As a research-based pharmaceutical company, Stallergenes says it invests 20% of its sales in research and development of forms of therapy.
At the end of 2015, the company had to temporarily stop delivering its pharmaceuticals due to a production error. Production and sales were resumed in February 2016.
In 2015, merged the company with Greer Laboratories . The company headquarters was relocated to London. The Paris stock exchange listing was discontinued in 2019.
Web links
Individual evidence
- ↑ a b Leadership. In: stallergenesgreer.com. Retrieved February 26, 2020 .
- ↑ a b Annual Report 2018. In: stallergenesgreer.com. Retrieved February 26, 2020 .
- ↑ Stallergenes Greer at a glance. In: Stallergenes Greer website. Retrieved February 26, 2020 .
- ↑ STALLERGENES reports FDA approval of ORALAIR, the first sublingual immunotherapy tablet for the treatment of grass pollen allergies , April 2, 2014.
- ↑ Delivery stop at Stallergenes . ( Memento of August 3, 2016 in the Internet Archive ) Apotheke Adhoc, December 10, 2015
- ↑ Press release StallergenesGreer , February 1, 2016
- ↑ a b History. In: stallergenesgreer.com. Retrieved February 26, 2020 .